CAR T-cell therapies combine cellular therapy, gene therapy and immune therapy to use a patient’s own T-cells to fight cancers. It is this potential for harnessing our immune systems to fight cancer that makes CAR T-cell therapies so revolutionary and earns them the name, “living drugs”.
Syngene is contributing to this revolutionary field by helping our clients evaluate their novel medicines/molecules for their mode of action, in vivo functional efficacy and other vital characteristics. Our end-to-end in vitro and in vivo immuno-oncology assessment platform allows fast and accurate validation of treatment approaches.
Our capabilities in supporting CAR-T cell research
- Design of CAR constructs
- CRISP-R gene editing
- Primary T-cell assays
- Human PBMCs isolation, sorting
- Cytotox assay with co-cultured cancer cells
- Proliferation
- Cytokine profile
- Virus generation for CAR delivery
- Lentivirus packaging
- Transduction efficiency
- Efficacy studies in syngeneic models
- Ex-vivo immuno-phenotyping of TILs
- PDX and humanized mouse models
- Preclinical evaluation
- In vivo proliferation of effector cells: CAR expression and CFSE assay
- Xenograft tumor growth inhibition (NOG-SCID mice)
- Survival as endpoint
- Whole animal imaging — Biodistribution
- Biorepositories
- Collaboration with multiple local and national medical centers for healthy and patients’ samples (blood, tissues)
- Currently banking >200 healthy donor PBMC ready to use
